In the sample of 13.75% of total NK cells, 4.1% of CD56+bright NK cells and 9.65% of CD56+dim NK cells were found GSK3235025 to express GNLY compared to the isotype-matched control (0%). The chart in Fig. 3A shows significantly lower expression of the CD56 molecule in
the CD3− CD56+dim subset compared to the CD3− CD56+bright subset (P < 0.0001), as it is determined by MFI. In patients with NSTEMI, the frequency of GNLY-positive total NK cells was elevated on day 7 after an acute coronary event compared to healthy examinees and to patients with NSTEMI on days 1, 14 and 21 (Fig. 4B). The lowest frequency of GNLY-positive cells was found on day 14 after an acute coronary event, which is significantly lower than on days 7 and 21, although it did not differ from day 28 or from the healthy controls (Fig. 4B). In both NK subsets, the percentage of cells expressing GNLY was higher on day 7 compared to on days 1 and 14 after MI and to healthy controls (Fig. 4C,D). In general, the MFI of GNLY basically did not change in NK cells (Fig. 3). In healthy examinees, NK cells from freshly isolated PBL spontaneously induced apoptosis of NK-sensitive K562 target cells in a 18-h cytotoxicity assay from 5 to 15% depending on the effector to target
cell ratio, ranging from 6:1 to 50:1 (Fig. 4A). Anti-perforin mAb almost completely abrogated apoptosis at effector to target ratios from 12:1 to 50:1, as did the combination of anti-perforin and anti-GNLY mAbs, whereas anti-GNLY IWR-1 cost mAb alone was ineffective at abolishing apoptosis (Fig. 4A). On days 7 and 28 after an acute coronary event, the apoptosis of K562 cells was significantly inhibited by
the addition oxyclozanide of anti-perforin mAb, anti-GNLY mAb, and the combination of anti-perforin and anti-GNLY mAbs at effector to target cell ratios of 50:1 and 25:1 (Fig. 4B). On day 14, apoptosis was generally negligible (Fig. 4B). On day 21, anti-perforin mAb and a combination of anti-perforin and anti-GNLY mAbs significantly decreased K562 apoptosis at ratios of 50:1 and 25:1, whereas anti-GNLY mAb by itself was ineffective (Fig. 4B). A negligible percentage of gated K562 cells expressed MHC class I molecules (1.2%) on the surface compared to the isotype-matched control, as was shown in the representative sample (Fig. 4C). In all experiments, the apoptosis of K562 cells and lymphocytes cultured in medium alone was comparable and was <15% (Fig. 4C). In leucocyte infiltrations, CD3+ and CD56+ cells were found rarely, but they were present (Fig. 5A). The double labelling of paraffin-embedded myocardial tissue sections from patients who died in the first week after an acute coronary event confirmed the presence of GNLY in cells with a CD3+ and CD56+ phenotype, compared to the isotype-matched control (Fig. 5A). CD3+ cells expressing GNLY were found more often than GNLY-expressing CD56+ cells (Fig. 5A). In patients who died late after an acute coronary event, a thinning and loss of myofibrils were observed (Fig.